ARTHEX biotech
Drug discovery and microRNAs
involvement in neuromuscular diseases
The first product of the company, ARTHEx-01
Expertes in Biochemistry, DNA and neurology
About us
ARTHEx Biotech S.L. is a spin-off company of the University of Valencia that is developing antisense RNA treatments against genetic diseases. Our team has a strong background on drug discovery and microRNAs involvement in neuromuscular diseases. We are supported by world-renowned scientific and clinical advisors that will facilitate the successful development of our products.
Our main objective is finding effective treatments to unmet medical needs. The first target of the company will be Myotonic Dystrophy Type 1 (DM1), which is an orphan disease affecting more than 900.000 people worldwide (estimated prevalence 1/8000). Our research reveled new therapeutic targets to treat the disease. The target and the mechanism of action of our molecules is new, and no other competitor has developed a similar approach.
